6.2 C
New York
Tuesday, November 17, 2026

GLP-1 Exit Strategy: Surgery and Switching Beat Stopping

Must read

Trends News Stories Editorial
Trends News Stories Editorialhttps://trendsnewsstories.com/
Editorial desk at Trends News Stories (trendsnewsstories.com), an independent news site based in New Delhi, India. We publish original trending-news explainers across entertainment, sports, tech, business and health. Facts are checked against official sources and trusted outlets; we credit sources, note what is unconfirmed, and correct errors when we find them.

Patients who stop GLP-1 weight loss drugs face a hard choice about what comes next, and choosing a GLP-1 exit strategy matters. Surgery produced the largest weight loss over two years, switching between drugs came next, and stopping treatment with no replacement kept the least weight off.

The findings come from Cleveland Clinic researchers who tracked 20,486 adults with obesity or type 2 diabetes. The work was published in eClinicalMedicine and presented on 15 November at ObesityWeek 2026 in National Harbor, Maryland. Lead author Hamlet Gasoyan, of the clinic’s Center for Value-Based Care Research, led the analysis. It is the largest comparison yet of what happens after a GLP-1 exit strategy.

A clear GLP-1 exit strategy has been missing from clinical guidance, even though stopping the drugs is common. Real world data show that about 47 to 65 percent of patients stop GLP-1 drugs within 12 months, often because of cost, side effects or loss of insurance cover. Use of the drugs for weight loss in the United States rose to 11 percent of adults in 2026, up from 3 percent in 2024, according to Gallup.

Five paths after a GLP-1 exit strategy decision

The researchers compared five paths over two years, using health records from patients who had taken injectable semaglutide or tirzepatide for at least three months between 2021 and 2023. The group had a mean age of 56.7 years, 63 percent were women, and mean body mass index was 38.0. The five paths were staying on the first drug, switching between semaglutide and tirzepatide, switching to another obesity drug, having metabolic and bariatric surgery, or stopping treatment.

Surgery produced the largest average loss, at 26.6 percent of body weight at two years. Switching between semaglutide and tirzepatide was linked to 16 percent weight loss, staying on the first drug to 10.9 percent, and switching to another obesity drug to 8.1 percent. Patients who stopped treatment were still 3.9 percent below their starting weight at two years, the smallest change of the five groups.

Switching drugs beat staying put for some patients

Among patients who started on semaglutide, switching to tirzepatide was linked to about 3 kilograms more weight loss at two years than staying on semaglutide. The pattern ran the other way for patients who started on tirzepatide: staying on it was linked to about 4.5 kilograms more weight loss than switching to semaglutide. The study used a method called target trial emulation, which uses health records to mimic the design of a clinical trial.

The researchers stressed that the work shows links between GLP-1 exit strategy paths and weight change, not proof that one path caused the extra loss. Patients who had surgery may have differed from drug treated patients in weight and health at the start, and they had to meet eligibility rules and face recovery time and surgical risks.

Why stopping without a GLP-1 exit strategy leads to regain

Earlier trials explain why a planned GLP-1 exit strategy matters. In the STEP 1 extension, people who had lost about 17 percent of their body weight on semaglutide regained roughly two thirds of it within a year of stopping, settling at about 5 percent below where they started. A meta-analysis in The BMJ found that people returned to their pretreatment weight an average of 1.7 years after stopping.

Appetite returns quickly once the drugs are stopped, because the drugs work in part by reducing hunger and slowing the stomach. Gasoyan said the results could support talks between patients and clinicians about other options when they think about switching or stopping injectable semaglutide or tirzepatide. The study also found that patients who stopped treatment had the least improvement in blood sugar control and blood pressure.

What patients should discuss with a clinician

The authors said the findings do not point to one GLP-1 exit strategy for every patient. Surgery is not an option for everyone, and switching drugs depends on cost, cover and tolerance. Patients who cannot stay on a GLP-1 can talk with a clinician about tapering the dose, switching drugs, or adding structured diet and exercise support before they stop.

For now, the clearest message from the study is that stopping with no plan kept the least weight off. A GLP-1 exit strategy that keeps some form of treatment in place, whether surgery, a switch to another drug, or continued use of the first drug, was linked to larger weight loss at two years than stopping outright.

More articles

Latest article